Replies to post #25613 on Viropro, Inc. (VPRO)

[BeamMeUpScotty]

In reply to number 2 I'd not at all be surprised if Axiom was the recipient of some of those government funds to develop what they think are promising trials

As Royston had strong links with the Clinton administration there's every possibility that a treatment he thinks looks promising would be more likely to be successful in a grant application

Best thing about grants - you don't have to pay them back and there's no dilution

[Lord_of_Trades]

Great, thanks for the actual response, instead of the accusations that I sold and want back lower and all that crap. This thing is clearly holding all its major moving averages, so anyone doing that is an idiot. I simply wanted some more informed investors, who've been watching this one longer, to give me their thoughts.

Your first point was exactly the breakdown I was looking for (i.e., what are the targets for the new PIII study compared to current baseline). Seems like it will be a pretty solid result if they can replicate the prior conditions; just need to make sure the trial is formatted correctly this time... especially since they even had an SPA the last go-round. I mean, for God's sake, whoever wrote that SPA royally screwed up if the results of the sub groups came out that favorably!

The second point is fair, and the industry has changed significantly. I'm glad to see he personally made commentary to it (I still need to verify that part). The advent and approval of checkpoint inhibitors was a huge step forward for the immunotherapy industry in general.

Thanks again for the help, and yes, that was even a key point in the most recent state of the union. The industry has been lagging in getting the federal grants into the more progressive industries, but it looks like that may just now beginning to change.

Good Luck to ALL

-Lord